4 GY involved field radiotherapy induces rapid and lasting remissions without significant toxicity in 200 B-cell lymphoma patients

被引：0
|
作者：
Haas, R
Poortmans, P
Aleman, B
Dewit, L
de Jong, D
Verheij, M
Bartelink, H
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Bernard Verbeeten Inst, Dept Radiotherapy, Tilburg, Netherlands
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
242
引用
收藏
页码：108 / 108
页数：1
相关论文
共 37 条
  • [21] Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease
    Bernd Metzner
    Jutta Welzel
    Thomas H. Müller
    Jochen Casper
    Christoph Kimmich
    Eduard K. Petershofen
    Andrea Renzelmann
    Bernd Rosien
    Ruth Thole
    Andreas Voss
    Kay Willborn
    Claus Henning Köhne
    [J]. Strahlentherapie und Onkologie, 2022, 198 : 39 - 46
  • [22] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL)
    Murray, JL
    Witzig, TE
    Molina, A
    Gordon, L
    Emmanouilides, C
    Vo, K
    Flinn, IW
    Czuczman, M
    Saville, W
    Wiseman, G
    White, CA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S48 - S49
  • [23] Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
    Persky, Daniel O.
    Unger, Joseph M.
    Spier, Catherine M.
    Stea, Baldassarre
    LeBlanc, Michael
    McCarty, Matthew J.
    Rimsza, Lisa M.
    Fisher, Richard I.
    Miller, Thomas P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2258 - 2263
  • [24] CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation
    Park, Yeon Hee
    Lee, Se-Hoon
    Kim, Won Seog
    Bang, Soo-Mee
    Ryoo, Baek-Yeol
    Yang, Sung Hyun
    Lee, Seung-Sook
    Kim, Mi Sook
    Kim, Kihyun
    Park, Keon Woo
    Im, Do Hyoung
    Kang, Jung Hun
    Lee, Jeeyun
    Ko, Young H.
    Ahn, Yong Chan
    Lim, Do Hoon
    Park, Keunchil
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1253 - 1259
  • [25] Phase I/II study of rituxan (R) in combination with doxil (D) in patients (pts) with relapsing or refractory B-cell lymphoma: Clinical efficacy without cardiac toxicity
    Czuczman, Myron S.
    Skipper, Marion
    Mohr, Alice
    Bernstein, Zale P.
    Hernandez-Ilizaliturri, Francisco J.
    Chanan-Khan, Asher A.
    [J]. BLOOD, 2007, 110 (11) : 411A - 412A
  • [26] Relapsed and primary refractory diffuse large B-Cell lymphoma: Improving outcome by incorporating involved field radiotherapy into a comprehensive second-line high-dose therapy strategy.
    Hoppe, Bradford S.
    Yahalom, Joachim
    Kewalramani, Tatun
    Hamlin, Paul A.
    Rice, David
    Filippa, Daniel
    Miragulia, Jocelyn
    Weaver, Alandra
    Moskowitz, Craig H.
    [J]. BLOOD, 2007, 110 (11) : 561A - 562A
  • [27] Subcutaneous epcoritamab induces durable complete remissions in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: long-term results from the EPCORE NHL-1 Phase 2 expansion cohort
    Scholz, C. W.
    Karimi, Y.
    Ghesquieres, H.
    Jurczak, W.
    Cheah, C. Y.
    Clausen, M. R.
    Lugtenburg, P.
    Cunningham, D.
    Do, Y. R.
    Lewis, D. J.
    Gasiorowski, R.
    Kim, T. M.
    van der Poel, M.
    Poon, M. L.
    Feldman, T.
    Linton, K. M.
    Sureda, A.
    Hutchings, M.
    Stirner, Cota M.
    Liu, Y.
    Kilavuz, N.
    Sacchi, M.
    Thieblemont, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 268 - 269
  • [28] Yttrium 90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy (RIT) induces durable remissions in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL):: Analysis of long-term responders.
    Witzig, TE
    Molina, A
    Gordon, LI
    Emmanouilides, C
    Schilder, RJ
    Flinn, I
    Czuczman, M
    Wang, H
    Theuer, C
    Wiseman, G
    [J]. BLOOD, 2003, 102 (11) : 407A - 407A
  • [29] Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313).
    Miller, Thomas P.
    Unger, Joseph M.
    Spier, Catherine
    Stea, Baldassarre
    Press, Oliver W.
    Friedberg, Jonathan W.
    LeBlanc, Michael
    Fisher, Richard I.
    [J]. BLOOD, 2008, 112 (11) : 1231 - 1231
  • [30] Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial
    Karimi, Yasmin
    Ghesquieres, Herve
    Jurczak, Wojciech
    Cheah, Chan Y.
    Clausen, Michael Roost
    Lugtenburg, Pieternella
    Cunningham, David
    Do, Young Rok
    Lewis, David John
    Gasiorowski, Robin
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Feldman, Tatyana
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Stirner, Mariana Cota
    Liu, Yan
    Kilavuz, Nurgul
    Sacchi, Mariana
    Thieblemont, Catherine
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S438 - S438
1234